HMG CoA reductase inhibitors
- 1 February 1991
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 2 (1) , 24-30
- https://doi.org/10.1097/00041433-199102000-00006
Abstract
The mechanism of action and clinical efficacy of lovastatin, simvastatin and pravastatin as hypolipidemic agents is reviewed. All three drugs act primarily in the liver and reduce plasma concentrations of low-density lipoprotein and very-low-density lipoprotein remnants by 30–50%. Serious side effects involving the liver or muscle are uncommon; the risk of myopathy is, however, increased when lovastatin is combined with gemfibrozil and this combination is not recommended.Keywords
This publication has 0 references indexed in Scilit: